Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trialLaura M. Spring, Aditya Bardia, Sarah A. McLaughlin et al.|Annals of Oncology|2023Cited by 77
Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.Rachel O. Abelman, Aditya Bardia, Laura M. Spring et al.|Journal of Clinical Oncology|2023Cited by 53
Abstract PS08-03: Sequencing Antibody-Drug Conjugate after Antibody-Drug Conjugate in Metastatic Breast Cancer (A3 study): Multi-Institution Experience and Biomarker AnalysisRachel O. Abelman, Aditya Bardia, Laura M. Spring et al.|Cancer Research|2024Cited by 21
Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter SyndromeErin M. Parry, Catherine J. Wu, Romain Guièze et al.|Blood|2022Cited by 10
Abstract 3888: <i>TOP1</i> mutations mediate cross resistance to ADCs in metastatic breast cancerRachel O. Abelman, Aditya Bardia, Haley Barnes et al.|Cancer Research|2024Cited by 2